XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Reverse Merger (Tables) - OncoGenex Pharmaceuticals, Inc [Member] | 9 Months Ended
--- | ---
Sep. 30, 2017
Business Acquisition [Line Items] |
Summary of Final Purchase Price | The final purchase price is summarized as follows (dollars in thousands, except per share amounts):
Shares of the combined company to be owned by OncoGenex equity holders |  |  | 2,736,709 |
Multiplied by the price per share of OncoGenex stock |  | $ | 4.62 |
Value of shares of the combined company owned by OncoGenex equity holders |  | $ | 12,643 |
Fair value of options and warrants assumed |  | $ | 207 |
Fair value of contingent value rights assumed |  | $ | 200 |
Total purchase price |  | $ | 13,050 |
Summary of Final Purchase Price Allocation | The final purchase price allocation is as follows (in thousands):
Cash, cash equivalents and marketable securities |  |  | 12,376 |
Prepaid expenses and other assets |  |  | 518 |
Intangible assets license agreements |  |  | 8,610 |
Accounts payable, accrued expenses and other liabilities |  |  | (4,054 | )
Deferred tax liability |  |  | (2,928 | )
Contingent value rights |  |  | (200 | )
Excess negative goodwill |  |  | (1,272 | )
Total purchase price |  |  | 13,050 |
Summary of Pro Forma Results of Operation |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2017 |  |  | 2016 |  |  | 2017 |  |  | 2016 |
Revenue |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 5,062 |
Net loss applicable to common shareholders |  | $ | (9,730 | ) |  | $ | (4,197 | ) |  | $ | (10,100 | ) |  | $ | (15,034 | )
Net loss per share-basic and diluted |  | $ | (1.35 | ) |  | $ | (0.14 | ) |  | $ | (4.15 | ) |  | $ | (0.50 | )
Weighted average shares |  |  | 7,225,826 |  |  |  | 30,013,928 |  |  |  | 2,435,095 |  |  |  | 29,925,479 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)-(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=achv_OncoGenexPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |